To include your compound in the COVID-19 Resource Center, submit it here.

Confo’s €30M growth plan

BioGeneration, Wellington lead series A for GPCR agonist company Confo

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round, announced on

Read the full 374 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE